AstraZeneca has lifted the veil on the large-scale THALES trial of its antiplatelet drug Brilinta in stroke, the company’s last big hope for recouping its substantial investmen
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
